Mabworks
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mabworks - overview
Established
2003
Location
Beijing, Beijing, China
Primary Industry
Pharmaceuticals
About
Established in 2003 and based in Beijing, China, Mabworks operates as a biopharmaceutical company dedicated to developing antibody drugs. It has more than 50 domestic and foreign invention patents. The chairman of the company, Feng Li graduated from Rice University and has worked in Genentech, Amgen, and Tanox. The CMO of the company, Jinjin Liang graduated from the University of California and has worked in Icon, WuXi Clinical, and IQVIA.
In March 2023, Mabworks was listed on the New Third Board. In March 2024, the company raised CNY 217. 99 million in strategic investment from new investor CGP Investment and returning investor E-Town International Industrial Investment. The company focuses on the development of antibodies that stimulate the immune system to deplete target pathogenic cells.
It has three technical platforms, including ADCC (antibody-dependent cell-mediated cytotoxicity) enhanced antibody platform, multi-specific antibody platform, and antibody discovery and optimization platform. The ADCC enhanced antibody platform is an antibody glycosylation modification platform, and the company is developing four clinical stage antibody drugs, including MIL62, MIL93, MIL97, and MBS301. Mabworks has developed 8 clinical stage drugs under research. The drugs cover the fields of tumours and autoimmune diseases.
In 2022, the company's revenue was CNY 15. 89 million, and its net income was CNY -251. 85 million.
Current Investors
GTJA Investment Group, Harvest Fund Management, E-Town International Industrial Investment
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.mab-works.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Mabworks - financials
| Fiscal Year Ended | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|
| Revenue (USD) | - | - | - |
| % Revenue Growth (YoY) | - | - | - |
| EBITDA (USD) | - | - | - |
| Operating Income (USD) | - | - | - |
| Operating Margin | - | - | - |
| % EBITDA Margin | - | - | - |
| NET Income (USD) | - | - | - |
| % Net Margin | - | - | - |
Mabworks - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer & General Manager | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.